Immunic (NASDAQ:IMUX) Given “Buy” Rating at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Immunic (NASDAQ:IMUX) in a report issued on Tuesday,Benzinga reports. The brokerage currently has a $17.00 price objective on the stock.

IMUX has been the subject of several other research reports. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Immunic in a research report on Friday, February 21st. William Blair started coverage on shares of Immunic in a research note on Tuesday, March 25th. They issued an “outperform” rating on the stock. Finally, StockNews.com cut shares of Immunic from a “hold” rating to a “sell” rating in a research report on Thursday, March 20th. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $12.67.

Immunic Stock Down 2.3 %

Shares of IMUX stock opened at $1.07 on Tuesday. The firm has a market cap of $95.93 million, a price-to-earnings ratio of -0.87 and a beta of 1.89. Immunic has a 12 month low of $0.92 and a 12 month high of $2.11. The stock has a 50-day moving average price of $1.09 and a 200 day moving average price of $1.20.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. State Street Corp raised its holdings in Immunic by 7.5% in the third quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after purchasing an additional 11,642 shares during the period. Jane Street Group LLC raised its stake in Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after buying an additional 38,553 shares during the period. Virtu Financial LLC bought a new position in Immunic during the third quarter worth about $50,000. HB Wealth Management LLC acquired a new position in Immunic in the fourth quarter valued at about $81,000. Finally, Invesco Ltd. bought a new stake in shares of Immunic in the fourth quarter worth about $37,000. Institutional investors and hedge funds own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.